HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Monitoring for post-injection delirium/sedation syndrome with long-acting olanzapine during the COVID-19 pandemic.

AuthorsDan Siskind, Korinne Northwood, Michael Berk, David Castle, Cherrie Galletly, Anthony Harris
JournalThe Australian and New Zealand journal of psychiatry (Aust N Z J Psychiatry) Vol. 54 Issue 7 Pg. 759-761 (Jul 2020) ISSN: 1440-1614 [Electronic] England
PMID32406764 (Publication Type: Letter)
Chemical References
  • Antipsychotic Agents
  • Delayed-Action Preparations
  • Olanzapine
Topics
  • Antipsychotic Agents (adverse effects)
  • Australia (epidemiology)
  • Betacoronavirus
  • COVID-19
  • Conscious Sedation (statistics & numerical data)
  • Coronavirus Infections (epidemiology)
  • Databases, Factual
  • Delayed-Action Preparations (adverse effects)
  • Delirium (chemically induced, epidemiology)
  • Drug Monitoring (statistics & numerical data)
  • Humans
  • Incidence
  • Olanzapine (adverse effects)
  • Pandemics
  • Pneumonia, Viral (epidemiology)
  • SARS-CoV-2
  • Syndrome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: